These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 12587817)
1. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Novak BL; Force RW; Mumford BT; Solbrig RM Pharmacotherapy; 2003 Feb; 23(2):265-9. PubMed ID: 12587817 [TBL] [Abstract][Full Text] [Related]
3. [Erythropoietin and arterial hypertension in patients with chronic renal insufficiency]. Simon P Rev Med Interne; 1995; 16(6):457-61. PubMed ID: 7652230 [TBL] [Abstract][Full Text] [Related]
4. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877 [TBL] [Abstract][Full Text] [Related]
8. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients. Walter J; Gål J; Taraba I Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644 [TBL] [Abstract][Full Text] [Related]
9. The use of subcutaneous erythropoietin in CAPD patients. Piraino B; Johnston JR Clin Nephrol; 1990 Apr; 33(4):200-2. PubMed ID: 2350907 [TBL] [Abstract][Full Text] [Related]
10. Erythropoietin hypertension: fact or fiction? Dorhout Mees EJ; Ok E Int J Artif Organs; 1997 Aug; 20(8):415-7. PubMed ID: 9323502 [No Abstract] [Full Text] [Related]
11. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523 [No Abstract] [Full Text] [Related]
13. Erythropoietin and arterial hypertension. Luft FC Clin Nephrol; 2000 Feb; 53(1 Suppl):S61-4. PubMed ID: 10746808 [TBL] [Abstract][Full Text] [Related]
14. Uraemia is necessary for erythropoietin-induced hypertension in rats. Poux JM; Lartigue M; Chaisemartin RA; Galen FX; Leroux-Robert C Clin Exp Pharmacol Physiol; 1995 Oct; 22(10):769-71. PubMed ID: 8575115 [TBL] [Abstract][Full Text] [Related]
15. [Rapid, progressive deterioration of renal function following erroneous administration of high doses of subcutaneous recombinant erythropoietin]. Buemi M; Allegra A; Aloisi C; Corica F; Frisina N Riv Eur Sci Med Farmacol; 1996; 18(1):39-42. PubMed ID: 8766781 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin-induced elevation in blood pressure is immediate and dose dependent. Ifudu O; Dawood M; Homel P Nephron; 1998 Aug; 79(4):486-7. PubMed ID: 9689173 [No Abstract] [Full Text] [Related]
17. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Carlini R; Obialo CI; Rothstein M Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228 [TBL] [Abstract][Full Text] [Related]
18. Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis. Ongkingco JR; Ruley EJ; Turner ME Am J Kidney Dis; 1991 Oct; 18(4):446-50. PubMed ID: 1928063 [TBL] [Abstract][Full Text] [Related]
19. The use of sublingual nifedipine in a patient with a clonidine overdose. Dire DJ; Kuhns DW J Emerg Med; 1988; 6(2):125-8. PubMed ID: 3290324 [TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Ishimitsu T; Tsukada H; Ogawa Y; Numabe A; Yagi S Am J Med; 1993 Apr; 94(4):401-6. PubMed ID: 8475933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]